Evidence map›Paper›PMID 31044348›Full record

ArticlePharmacoEconomics2019

Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".

R Brett McQueen, Melanie D Whittington, Rick H Chapman, Varun M Kumar, Jonathan D Campbell

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in PharmacoEconomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

R Brett McQueenCenter for Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Mail Stop C238, 12850 E Montview Blvd., Aurora, CO, 80045, USA. Robert.mcqueen@ucdenver.edu.ORCID 0000-0002-4302-2678
Melanie D WhittingtonCenter for Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Mail Stop C238, 12850 E Montview Blvd., Aurora, CO, 80045, USA.
Rick H ChapmanInstitute for Clinical and Economic Review, Boston, MA, USA.
Varun M KumarInstitute for Clinical and Economic Review, Boston, MA, USA.
Jonathan D CampbellCenter for Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Mail Stop C238, 12850 E Montview Blvd., Aurora, CO, 80045, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Ovarian NeoplasmsCost-Benefit AnalysisFemaleHumansIndazolesIndolesPhthalazinesPiperazinesPiperidinesUnited StatesIndazolesIndolesniraparibolaparibPhthalazinesPiperazinesPiperidinesrucaparib

Identifiers

PMID31044348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.